Preclinical Research
Test Your Knowledge of PCR Applications
PCR testing continues to be in the spotlight as a reliable way of screening for COVID-19 and other viruses in patients. Its amplification process enables it to detect small portions of genetic material in these viruses. But PCR can be also used for a broad range of additional applications.
[NEW PODCAST] Microsampling: When Small Steps Lead to Big Outcomes
Microsampling: When Small Steps Lead to Big Outcomes
Join us as Dr. Donald Chace and Jeff Plomley discuss the many advantages of incorporating microsampling into your drug development program.
Altasciences is at the forefront of microsampling, leveraging innovative technology that allows for significantly reduced blood volumes to be taken from test subjects for analysis. Our experts have developed specialized workflows and methods to take full advantage of current microsampling technology at the preclinical, clinical, and bioanalytical levels, supporting the efficient advancement of your drug development program. Our services are fully customizable, available as stand-alone, or as part of a complete development program.
You may also be interested in the following:
- The Altascientist: Microsampling in Drug Development
- Webpage: Patient Centricity and the Evolving Role of Microsampling
- Webpage: Comprehensive Bioanalytical Services
- PDF: Altasciences' Proprietary Bioanalytical Assay List
Transforming the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, Altasciences offers a unique integrated approach to CRO and CDMO s
Case Study―Safety Assessment of Intravitreal Implants in Dutch Belted Rabbits
Reduce Your Drug Development Costs and Delays
Benefit from Partnering with a Single CRO/CDMO Partner―From Formulation to Preclinical to Clinical
The drug development journey often involves working with different CRO and CDMO partners. But there’s a simpler, more efficient solution!
Altasciences’ fully integrated, end-to-end offering means seamless transition from prototype formulation through preclinical testing, to early phase clinical trials, and manufacturing. This reduces complex handoffs, communication errors, and delays.
Discover how we support you through each phase of your drug development.
Related pages:
- Webpage: Formulation, Development, and Manufacturing Solutions
- Virtual Tour: Manufacturing Facility and Analytical Laboratories
- Webinar: Overcoming Challenges of Manufacturing in Clinical Trials
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.
Accelerate the Development of Your CNS-Active Drugs with Pharmacodynamic Measures
Accelerate the Development of Your CNS-Active Drugs with Pharmacodynamic Measures
Strategic design and targeted use of pharmacodynamic measures can greatly assist in evaluating the safety and potential efficacy of your new drug candidate in the early stages of clinical development.
In this on-demand webinar, our experts discuss how to include validated models of pain, anxiety, and other psychiatric conditions as part of a battery of tests for cognition and safety, to evaluate a drug’s potential for abuse or dependence, as well as its ability to enhance or impair performance.
You may also be interested in the following:
- The Altascientist: Considerations for Your CNS-active Drug Development Program
- Webinar — Assessing Cognition and Driving Ability in Clinical Pharmacology Studies
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programmes, to offer an integrated/synchronized approach to CRO and CDMO services.
Safety Pharmacology Case Studies, Webinar On-Demand
You Won’t Want to Miss This Video!
Watch as, Dr. Michael R. Gralinski, CEO of CorDynamics, reviews the results of three GLP safety pharmacology validation studies.
The studies were conducted using telemetered dogs with well-characterized hemodynamic, electrocardiographic, and respiratory positive controls. All three studies demonstrated the ability to detect expected effects of positive controls with a high degree of reliability.
The studies were conducted in Altasciences' purpose-built, isolated telemetry facility, with data review and interpretation by CorDynamics.
Speak with one of our experts today.
You may also be interested in:
• The Altascientist: Scientific Journal Issue 13 — Safety Pharmacology Studies, a Review
• Fact Sheet: Safety Pharmacology
• Webpage: Safety Pharmacology Overview and FAQs
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services.
NEW SCIENTIFIC PUBLICATION — Achieve Robust and Accurate Study Results
Robust Sample Management
Read our latest issue of The Altascientist to better understand how we deliver reliable study results through robust sample management for your preclinical and Phase I to IV clinical studies, including:
- Customized processes
- Controlled environments
- Standardized workflows for risk management
- Capability to handle a wide variety of matrices
- Stability testing
Download your copy, or listen to the audiobook today.
You may also be interested in the following:
Webinars:
- Sample Collection Kits and Lab Manual
- Bioanalytical Project Management
- Critical Sample Handling Processes for Clinical and Preclinical Studies
Podcast:
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services.
The Reality Behind Schedule I Therapeutic Development
Altasciences Tackles the Issues and Challenges Associated with Schedule I Therapeutic Development
Schedule I, or Class I (CI) drugs are currently restricted to research in the U.S., meaning that they are not approved for medical use, and are deemed at highest risk for abuse. Recent research on psychedelics and entactogens, of which are schedule I, is beginning to demonstrate potential therapeutic effects of these drugs for various medical indications. Approvals of such drugs for medical or therapeutic use will inevitably result in the rescheduling of these drugs from their current CI status.
In this issue of The Altascientist, we uncover the following:
- Regulatory environment and challenges — DEA
- Required preclinical and clinical studies specific to Schedule I or Class I (CI) drugs
- Manufacturing considerations
For novel CNS-active Schedule I drugs, partner with Altasciences and benefit from our Schedule I licenses across every stage of early phase drug development. Our knowledge and operational expertise across preclinical, clinical, and manufacturing stages ensures complete continuity, data transfer, information sharing, and efficient timeline management... in real-time.
Speak with an expert today for more information or to review your specific program requirements.
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.
Delays Starting Your Nonhuman Primate Studies?
Want to Start Your Nonhuman Primate Studies in Q3 2022? Here’s How.
Are you experiencing delays initiating your nonhuman primate (NHP) studies? We have the capacity, at our three preclinical sites, to start your studies two to three months following contracting, thanks to our steady supply of NHPs.
At Altasciences, we do not rely on a single-source NHP supply chain. We remove the stress of sourcing research animals so that you can start your studies faster, with:
- Dedicated and diversified cynomolgus monkey supply agreements in place to allow for faster start-up timelines
- A continuously maintained and backfilled population of hundreds of naïve NHPs at our preclinical facility
You can schedule newly contracted NHP studies to start in Q3 2022 immediately.
Contact us to schedule your NHP studies today.
Have five minutes? Discover our extensive site capabilities:
- Webpage: Preclinical Testing Facilities
- Fact Sheet: Preclinical Services Capabilities
- The Altascientist: Planning Your Preclinical Assessment
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services.